Last reviewed · How we verify
SMOFlipid (baseline)
SMOFlipid is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.
SMOFlipid is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally. Used for Parenteral nutrition in patients unable to maintain adequate oral or enteral intake, Nutritional support in critical illness, post-operative states, and gastrointestinal dysfunction.
At a glance
| Generic name | SMOFlipid (baseline) |
|---|---|
| Also known as | SMOFlipid 20% Fresenius Kabi |
| Sponsor | General University Hospital, Prague |
| Drug class | Lipid emulsion for parenteral nutrition |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
SMOFlipid is a composite lipid emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil (omega-3 fatty acids). It is administered intravenously as part of total parenteral nutrition (TPN) to supply energy, essential fatty acids, and fat-soluble vitamins to patients with severe malnutrition, gastrointestinal dysfunction, or critical illness.
Approved indications
- Parenteral nutrition in patients unable to maintain adequate oral or enteral intake
- Nutritional support in critical illness, post-operative states, and gastrointestinal dysfunction
Common side effects
- Hypertriglyceridemia
- Phlebitis at infusion site
- Hepatic steatosis with prolonged use
- Lipid overload syndrome
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |